Cargando…

Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence

Detalles Bibliográficos
Autores principales:	Khambholja, Kapil, Asudani, Deepak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252084/ https://www.ncbi.nlm.nih.gov/pubmed/32360327 http://dx.doi.org/10.1016/j.tmaid.2020.101710

Ejemplares similares

Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment
por: Kelleni, Mina T.
Publicado: (2021)

Role of favipiravir in the treatment of COVID-19
por: Joshi, Shashank, et al.
Publicado: (2021)

Potential of herbs in skin protection from ultraviolet radiation
por: Korać, Radava R., et al.
Publicado: (2011)

Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors
por: Langendries, Lana, et al.
Publicado: (2021)

Current Therapeutic Trends for Tinnitus Cure and Control: A Scoping Review
por: Chhaya, Vatsal, et al.
Publicado: (2023)

Future of antivirals in COVID-19: The case of favipiravir
por: Kow, Chia Siang, et al.
Publicado: (2022)

Evaluation of the effect of favipiravir on patients with COVID-19
por: Kamali, Alireza, et al.
Publicado: (2023)

Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms
por: Hoertel, Nicolas, et al.
Publicado: (2021)

Favipiravir for COVID-19 in a Patient on Hemodialysis
por: Hirai, Daisuke, et al.
Publicado: (2021)

Population pharmacokinetics of favipiravir in patients with COVID‐19
por: Irie, Kei, et al.
Publicado: (2021)

Use of Favipiravir in Lactating Mother With COVID-19
por: Karabayır, Nalan, et al.
Publicado: (2021)

Hematological Malignancy Patients, COVID-19, and Favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
por: Pilkington, Victoria, et al.
Publicado: (2020)

Favipiravir exposure and pregnancy outcome of COVID-19 patients
por: Tırmıkçıoğlu, Zeynep
Publicado: (2022)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021)

Effect of favipiravir and an anti-inflammatory strategy for COVID-19
por: Yamamura, Hitoshi, et al.
Publicado: (2020)

Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19
por: Irie, Kei, et al.
Publicado: (2020)

Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
por: Korman, Tony M.
Publicado: (2021)

PIONEER trial: favipiravir to treat moderate COVID-19
por: Shalhoub, Sarah
Publicado: (2023)

Repurposing and reshaping of hospitals during the COVID-19 outbreak in South Korea
por: Her, Minyoung
Publicado: (2020)

Favipiravir: A new and emerging antiviral option in COVID-19
por: Agrawal, Umang, et al.
Publicado: (2020)

Effectiveness of favipiravir in COVID-19: a live systematic review
por: Özlüşen, Batu, et al.
Publicado: (2021)

Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients
por: Tawfik, Abdulrahman, et al.
Publicado: (2022)

Regional trends in the use of steroids and favipiravir for COVID-19 treatment
por: Asai, Yusuke, et al.
Publicado: (2023)

Potential for the Repurposing of Adamantane Antivirals for COVID-19
por: Butterworth, Roger F.
Publicado: (2021)

An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand
por: Sarojvisut, Phahol, et al.
Publicado: (2023)

A Favipiravir-induced Fever in a Patient with COVID-19
por: Kurita, Takashi, et al.
Publicado: (2020)

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19
por: Ison, Michael G., et al.
Publicado: (2021)

Favipiravir Experience in Covid-19 Positive Myasthenia Gravis Patients
por: Yevgi, Recep, et al.
Publicado: (2021)

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients
por: Chen, Ping-Jen, et al.
Publicado: (2021)

An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19
por: Karatas, Hacer, et al.
Publicado: (2022)

Favipiravir and hyperuricemia in patients with COVID-19—suggestions for future studies
por: Kow, Chia Siang, et al.
Publicado: (2023)

Current Status of Baricitinib as a Repurposed Therapy for COVID-19
por: Saber-Ayad, Maha, et al.
Publicado: (2021)

Flight of the COVID-19 patient: experience with a Wuhan evacuee: a case report
por: Segar, Sandeep, et al.
Publicado: (2020)

Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?
por: Ozsurekci, Yasemin, et al.
Publicado: (2021)

Favipiravir for symptomatic COVID-19: A nationwide observational cohort study
por: Doi, Yohei, et al.
Publicado: (2023)

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study()
por: Cai, Qingxian, et al.
Publicado: (2020)

ICU admission and favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences
por: Shiraki, Kimiyasu, et al.
Publicado: (2022)

Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone
por: Sood, Shivani, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0usarhbov06d2l1gie2cmf7r25